Acute Kidney Injury
Conditions
Keywords
renal replacement therapy, dialysis, acute kidney injury, hemodialysis, critical illness
Brief summary
The objectives of this trial are to determine whether, in critically ill patients with severe acute kidney injury (AKI), randomization to accelerated initiation of renal replacement therapy (RRT), compared with standard initiation, is: 1. Feasible, in terms of adherence to the protocol (primary outcome), recruitment rates, and achievement of follow-up; and 2. Safe, from the perspective of potential adverse events associated with earlier initiation of RRT
Detailed description
Acute kidney injury (AKI) is a common and devastating complication of critical illness. Once AKI is established, treatment is largely supportive and no intervention has been found to restore kidney function or improve overall survival. Renal replacement therapy (RRT), usually in the form of hemodialysis, is frequently needed to manage patients with severe AKI. Such patients have an in-hospital mortality that consistently exceeds 50%. Delay in the initiation of RRT has been implicated as a possible contributor to this poor outcome. A recent meta-analysis suggested that earlier initiation of RRT may improve survival. However, completed trials to date have been small, single centre, limited by study quality, and have shown considerable heterogeneity in terms of definitions used for early RRT initiation. The objectives of this trial are to determine whether, in critically ill patients with severe acute kidney injury (AKI), randomization to accelerated initiation of renal replacement therapy (RRT), compared with standard initiation, is: 1. Feasible, in terms of adherence to the protocol (primary outcome), recruitment rates, and achievement of follow-up; and 2. Safe, from the perspective of potential adverse events associated with the earlier or later initiation of RRT This pilot trial is intended to guide and inform the design of a phase III multicentre randomized trial of accelerated versus standard initiation of RRT in critically ill patients that will evaluate the impact of the intervention on 90-day all-cause mortality and recovery of kidney function.
Interventions
A dialysis catheter will be placed and RRT initiated as soon as possible and within 12 hours of eligibility. This 12 hour window includes the time needed to obtain consent.
Patients will be carefully followed over a period of 7 days to identify potential indications for RRT. The trial team will ask that the clinical team consider RRT initiation if there are: I. Criteria for persistent AKI (serum creatinine has not declined by more than 50% from value recorded at time of eligibility) AND II. At least one of the following indications for RRT initiation: 1. Serum potassium ≥6.0 mmol/L, or 2. Serum bicarbonate ≤ 10 mmol/L, or 3. Evidence of severe respiratory failure, based on a PaO2/FiO2 \<200 and bilateral infiltrates on the chest x-ray, or 4. By 72 hours after randomization, creatinine has not declined by more than 50% from that recorded at the time of randomization
Sponsors
Canadian Institutes of Health Research (CIHR)
Alere San Diego
Unity Health Toronto
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
(all of these need to be present): 1. Age ≥ 18 years 2. Admission to an intensive care unit 3. Evidence of kidney dysfunction (serum creatinine ≥ 100 µmol/L (women) or ≥ 130 µmol/L (men)) 4. Evidence of severe AKI defined by at least 2 of the following 3 criteria: i-A 2-fold increase in serum creatinine during hospitalization or from a known pre-hospitalization baseline ii-Oliguria as defined by total urine output \< 6 mL/kg over the preceding 12 hours iii-Whole blood Neutrophil Gelatinase-Associated Lipocalin (NGAL) ≥ 400ng/mL 5. Likelihood that an absolute indication for RRT will not arise in the subsequent 24 hours based on the most recent bloodwork for the following parameters: i- Serum potassium ≤ 5.5 mmol/L and ii- Serum bicarbonate ≥ 15 mmol/L 6. Central venous pressure ≥ 8 mmHg
Exclusion criteria
(the presence of one of these would disqualify eligibility): 1. Lack of commitment to ongoing life support 2. Presence of a drug overdose that necessitates initiation of RRT 3. Any RRT within the previous 2 months 4. Presence or clinical suspicion of renal obstruction, rapidly progressive glomerulonephritis, vasculitis, or acute interstitial nephritis 5. Advanced chronic kidney disease, defined by an estimated glomerular filtration rate \< 30 mL/min/1.73 m2, based on pre-hospitalization blood work 6. Kidney transplant within the past 365 days 7. At the time of screening, doubling of serum creatinine has been present for \> 48 hours 8. Clinician(s) caring for patient believe(s) that immediate dialysis is absolutely mandated 9. Clinician(s) caring for patient believe(s) that deferral of dialysis initiation is mandated 10. Patient or substitute decision maker can not provide consent within 12 hours of study eligibility
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Feasibility of protocol adherence | 14 days | \>90% of participants in the accelerated initiation arm start RRT within 12 hours of eligibility AND \>90% of participants randomized to the standard initiation arm who ultimately receive RRT, start RRT at least 12 hours following eligibility determination |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Feasibility of enrollment | 14 days | \>50% of eligible patients are successfully enrolled in the trial |
| Feasibility of 90-day follow-up | 90 days | Vital status and need for RRT at 90 days are successfully captured in \>95% of participants |
| Safety outcomes | 14 days | Serious adverse effects, with a particular focus on those that are potentially attributable to the study treatment, vascular accesss complications (including hemorrhage, thrombosis and infection) and complications associated with the delivery of RRT (dialysis-associated hypotension, electrolyte abnormalities) will be examined. |
Countries
Canada
Outcome results
None listed